NCT01972919View on ClinicalTrials.gov

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 10, 2015

Primary Completion Date

December 13, 2023

Study Completion Date

July 31, 2025

Conditions
Unresectable Pancreatic Cancer
Interventions
RADIATION

Radiation Therapy

Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.

DRUG

Concurrent chemotherapy (Gemcitabine, Capecitabine)

Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.

Trial Locations (1)

53226

Froedtert Hospital, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT01972919 - MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter